Literature DB >> 18614193

RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses.

Agnès Billecocq1, Nicolas Gauliard, Nicolas Le May, Richard M Elliott, Ramon Flick, Michèle Bouloy.   

Abstract

Rift Valley fever virus (RVFV, Bunyaviridae, Phlebovirus) is a mosquito-transmitted arbovirus that causes human and animal diseases in sub-Saharan Africa and was introduced into the Arabian Peninsula in 2000. Here, we describe a method of reverse genetics to recover infectious RVFV from transfected plasmids based on the use of the cellular RNA polymerase I promoter to synthesize viral transcripts. We compared its efficiency with a system using T7 RNA polymerase and found that both are equally efficient for the rescue of RVFV generating titers of approx. 10(7) to 10(8) pfu/ml. We used the RNA polymerase I-based system to rescue both attenuated MP12 and virulent ZH548 strains as well as chimeric MP12-ZH548 viruses, and in addition RVFV expressing reporter proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614193      PMCID: PMC2577904          DOI: 10.1016/j.virol.2008.05.033

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Efficient bunyavirus rescue from cloned cDNA.

Authors:  Anice C Lowen; Carol Noonan; Angela McLees; Richard M Elliott
Journal:  Virology       Date:  2004-12-20       Impact factor: 3.616

Review 2.  Rift Valley fever virus.

Authors:  Ramon Flick; Michèle Bouloy
Journal:  Curr Mol Med       Date:  2005-12       Impact factor: 2.222

3.  Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs.

Authors:  A Bridgen; R M Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication.

Authors:  Arnold Martin; Peter Staeheli; Urs Schneider
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene.

Authors:  Tetsuro Ikegami; Sungyong Won; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs.

Authors:  Gjon Blakqori; Friedemann Weber
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Persistent infection of mammalian cells by Rift Valley fever virus.

Authors:  A Billecocq; P Vialat; M Bouloy
Journal:  J Gen Virol       Date:  1996-12       Impact factor: 3.891

Review 8.  Rift Valley fever.

Authors:  G H Gerdes
Journal:  Rev Sci Tech       Date:  2004-08       Impact factor: 1.181

9.  Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA.

Authors:  Lukas Flatz; Andreas Bergthaler; Juan Carlos de la Torre; Daniel D Pinschewer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Rescue of the prototypic Arenavirus LCMV entirely from plasmid.

Authors:  Ana B Sánchez; Juan C de la Torre
Journal:  Virology       Date:  2006-02-14       Impact factor: 3.616

View more
  59 in total

1.  The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

Authors:  José-Carlos Fernandez; Agnès Billecocq; Jean Paul Durand; Catherine Cêtre-Sossah; Eric Cardinale; Philippe Marianneau; Michel Pépin; Noël Tordo; Michèle Bouloy
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Authors:  Nandadeva Lokugamage; Alexander N Freiberg; John C Morrill; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

4.  Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase.

Authors:  Birte Kalveram; Tetsuro Ikegami
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

5.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

6.  Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

7.  Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR.

Authors:  Birte Kalveram; Olga Lihoradova; Sabarish V Indran; Nandadeva Lokugamage; Jennifer A Head; Tetsuro Ikegami
Journal:  Virology       Date:  2012-10-12       Impact factor: 3.616

Review 8.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Generation of a Recombinant Akabane Virus Expressing Enhanced Green Fluorescent Protein.

Authors:  Akiko Takenaka-Uema; Yousuke Murata; Fumihiro Gen; Yukari Ishihara-Saeki; Ken-Ichi Watanabe; Kazuyuki Uchida; Kentaro Kato; Shin Murakami; Takeshi Haga; Hiroomi Akashi; Taisuke Horimoto
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

10.  Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.

Authors:  Brian B Gowen; Kevin W Bailey; Dionna Scharton; Zachery Vest; Jonna B Westover; Ramona Skirpstunas; Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2013-03-21       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.